comparemela.com

Page 20 - Minute Medicine Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms

1. In this randomized controlled trial, treatment with JNJ-77242113 improved psoriasis symptoms as compared to a placebo. 2. JNJ-77242113 showed a dose-response relationship, with higher doses eliciting stronger treatment effects. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriasis is an immune-mediated inflammatory disease primarily affecting the skin and joints. The immune process is mediated by Interleukin-23, which

Non-alcoholic fatty liver disease increases cardiovascular and mortality risk in patients with diabetes

1. The risk of cardiovascular disease (CVD) and all-cause death for individuals with type 2 diabetes mellitus (T2DM) is increased for those with non-alcoholic fatty liver disease (NAFLD) compared to those without NAFLD. Evidence Rating Level: 2 (Good) Non-alcoholic fatty liver disease (NAFLD) is increasing in prevalence globally. Patients with NAFLD are at an increased

Use of point-of-care ultrasound for inpatient care may improve patient satisfaction

1. The use of POCUS in an adult inpatient setting improved patient satisfaction with their overall care and perceived Evidence Rating Level: 3 (Average) Point-of-care ultrasound (POCUS) is a tool used to aid in decision-making at the bedside. While POCUS is used frequently in emergency departments, with increasing use in inpatient settings. Aside from the

#VisualAbstract: Electronic nicotine-delivery systems improve smoking cessation

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

#VisualAbstract: Stereotactic body radiotherapy enhances survival in patients with non-small cell lung cancer

1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT) is a

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.